|Videos|February 2, 2023
Additional Key Data Updates from ASH 2022 on Treatment of LBCL
Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5